inotuzumab ozogamicin,blinatumomab
pfizer,amgen,ucb pharmaceuticals
['leusm', 'blinatumomab', 'inotuzumab', 'inotuzumab ozogamicin']
#eha2023 | presents ph ii trial results on mini-hyper-cvd + inotuzumab ozogamicin blinatumomab in older pts with newly diagnosed ph-negative b-cell #all. 5-yr os was 48%. combination was well tolerated, no early deaths reported. #allsm #leusm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm